vedolizumab

targets

all catalysts(0)

nothing on the calendar yet

News(6)

• 5 NextGen winners who went public this year (and which ones are hiring)
  BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.
  biospace · 7d ago
• Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
  Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
  fiercebiotech · 9d ago
• Abivax shares surge as worries subside over immune drug’s cancer risk
  According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.
  biopharma_dive · 1mo ago
• cAMPfield lands $180M to build gut disease drug
  The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
  biopharma_dive · 1mo ago
• AbiVax falls as safety worries cloud ‘landmark’ immune drug results
  A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
  biopharma_dive · 2mo ago
• Odyssey, on second try, snags $279M in an IPO
  After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new biotech stock offerings — while boosting its haul even higher through a concu…
  biopharma_dive · 3mo ago